Skip to main content

Table 3 Ongoing phase III studies in front-line advanced/metastatic RCC

From: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma

Study Primary endpoint Sample size National clinical trial identifier Start time/status
Nivolumab + ipilimumab vs. sunitinib PFS, OS 1070 (1:1) NCT02231749 Oct 2014/on-going/enrollment closed
Atezolizumab + bevacizumab vs. sunitinib PFS, OS 900 (1:1) NCT02420821 May 2015/on-going
Avelumab + axitinib vs. sunitinib PFS, 583 (1:1) NCT02684006 March 2016/on-going
Pembrolizumab + axitinib vs. sunitinib PFS, OS 840 (1;1) NCT02853331 Sept 2016
Pembrolizumab + lenvatinib or everolimus + lenvatinib vs. sunitinib PFS 735 (1:1:1) NCT02811861 Sept 2016